Results
Objective responses were observed in 19 out of 78(24.36%) patients, and
the disease control rate (DCR) was 69.23% (54/78). No patient achieved
a complete response. The median progression-free survival (PFS) was 6.49
months (95% CI:3.71-9.27). PFS was 1.44 months (95%CI:0.00-4.34) for
monotherapy versus 7.34 months (95%CI:4.50-10.18) for combination
therapy (P=0.053). Patients in the first-line treatment group revealed
relatively higher ORR and longer PFS (ORR: 48.00% vs. 13.20%, P =
0.001; PFS: 7.67 months vs. 5.57 months, P = 0.129). Patients with
combined radiotherapy showed longer PFS than those without combined
radiotherapy (14.07 vs.4.62, P=0.027). The incidence of adverse events
of any grade was 73.07% (57/78), among which there were 7 cases of
grade 4 adverse events. The incidence of leukopenia in any grade of
adverse reactions was the highest (57.69%), followed by anemia
(25.64%), elevated alanine aminotransferase or aspartate
aminotransferase (24.36%) and fatigue (21.79%). Hepatic transaminase
increased in 26.7% (16/60) of HBV-infected patients, and remained
unchanged in 63.3% (38/60) patients.